Paul Tudor Jones Pliant Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 22,628 shares of PLRX stock, worth $300,952. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,628
Previous 32,246
29.83%
Holding current value
$300,952
Previous $346,000
26.88%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PLRX
# of Institutions
168Shares Held
63.2MCall Options Held
245KPut Options Held
373K-
Deep Track Capital, LP Greenwich, CT5.97MShares$79.4 Million2.47% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$66.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.83MShares$64.3 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$46.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.2MShares$42.5 Million2.34% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $647M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...